Emerging CSF and Serum Biomarkers in Multiple Sclerosis | Synapse
April 26, 2026Open Access
Emerging CSF and Serum Biomarkers in Multiple Sclerosis
Key Points
To identify CSF and serum biomarkers that can predict relapse activity and disease severity in multiple sclerosis.
Assessment of biomarkers in cerebrospinal fluid (CSF) and serum samples.
Evaluation of CXCL13, CXCL9, IL-12b in CSF and GFAP, MOG in serum as predictors.
CSF CXCL13, CXCL9, and IL-12b are promising for predicting relapse activity.
Serum GFAP and MOG consistently indicate disease severity.
Abstract
CSF CXCL13, CXCL9, and IL-12b are promising biomarkers for predicting relapse activity, while serum GFAP and MOG appear to be consistent candidates for prognosticating disease severity.